Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment

British Journal of Cancer

Volumn 96, Issue 2, 2007, Pages 206-212

  Starling, N ^a   Tilden, D ^b   White, J ^c   Cunningham, D ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b M TAG   (United Kingdom)

^c MERCK KGAA   (Germany)

Author keywords

Cetuximab; Colorectal; Cost effectiveness

Indexed keywords

CETUXIMAB; IRINOTECAN;

ARTICLE; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG TREATMENT FAILURE; HUMAN; LIFE EXPECTANCY; NATIONAL HEALTH SERVICE; PATIENT CARE; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; HUMANS; NEOPLASM METASTASIS; SALVAGE THERAPY; SURVIVAL ANALYSIS;

EID: 33846477195     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603561     Document Type: Article

References (31)

1. Barni S, Lissoni P, Cazzaniga M, Ardizzoia A, Meregalli S, Fossati V, Fumagalli L, Brivio F, Tancini G (1995) A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates. Oncology 52: 243-245
2. Brouwer W, van Hout B (1998) How should different life expectancies be valued? Diminishing marginal utility and discounting future effects have similar consequences. BMJ 317: 1155
3. Camidge R, Walker A, Oliver JJ, Nussey F, Maxwell S, Jodrell D, Webb DJ (2005) Prognosis without treatment as a modifier in health economic assessments. BMJ 330: 1382-1384
4. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23: 1803-1810
5. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van CE (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345
6. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352: 1413-1418
7. Data on File. Merck Pharmaceuticals.UKECRC05019
8. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le BN, Louvet C, Hendler D, de BF, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947
9. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047
10. Gelber RD, Goldhirsch A, Cole BF (1993) Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments. International Breast Cancer Study Group. Control Clin Trials 14: 485-499
11. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30
12. Grothey A, Sargent D, Goldberg RM, Schmoll HJ (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22: 1209-1214
13. Mason H, Marshall A, Jones-Lee M. Estimating a value of a QALY from existing UK values of prevented fatalities. The SVQ Research Team, 2006 page iv. http://www.ncl.ac.uk/chsr/abstractfull.htm
14. Meta-Analysis Project in Advanced Colorectal Cancer (1994) Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 12(5): 960-969
15. Meta-analysis Group In Cancer (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16(1): 301-308
16. National Institute for Clinical Excellence (2005) Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer (review of Technology Appraisal No. 33)
17. National Institute for Health and Clinical Excellence (2005) Health Technology Appraisal. The use of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Final Scope
18. Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156
19. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834
20. Perez-Soler R, Saltz L (2005) Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 23(22): 5235-5246
21. Petrou S, Campbell N (1997) Stabilisation in colorectal cancer. Int J Palliative Nurs 3(5): 275-280
22. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ (2002) Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 8: 994-1003
23. Rao S, Cunningham D, de GA, Scheithauer W, Smakal M, Humblet Y, Kourteva G, Iveson T, Andre T, Dostalova J, Illes A, Belly R, Perez-Ruixo JJ, Park YC, Palmer PA (2004) Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 22: 3950-3957
24. Rawlins MD, Culyer AJ (2004) National Institute for Clinical Excellence and its value judgments. BMJ 329: 224-227
25. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le BN, Haller DG (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21: 2059-2069
26. Saltz L, Rubin M, Hochster H, Tchekmeydian SN, Waksal H, Needle M, LoBuglio A (2001) Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). 2001 ASCO Annual Meeting. Abstract 7. (Updated information presented at meeting) www.asco.org/ac/1,1003,_12-002627-00_18-0010-00_19-007,00. asp
27. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914
28. Saltz LB, Meropol NJ, Loehrer Sr PJ, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: 1201-1208
29. Sculpher M, Claxton K (2005) Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty - when is there sufficient evidence? Value Health 8: 433-446
30. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de GA (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237
31. Waugh N, Scott D (1998) How should different life expectancies be valued? BMJ 316: 1316